The efficacy of the different endoscopic treatments versus sham, pharmacologic or surgical methods for chronic gastroesophageal reflux disease: a systematic review and meta-analysis

Martin Andrés CORONEL, Wanderley Marques BERNARDO, Diogo Turiani Hourneaux de MOURA, Eduardo Turiani Hourneaux de MOURA, Igor Braga RIBEIRO and Eduardo Guimarães Hourneaux de MOURA

ABSTRACT – Background – Endoscopic antireflux treatments for gastroesophageal reflux disease (GERD) are still evolving, and most of the published studies address symptom relief in the short-term. Objective – We aimed to perform a systematic review and meta-analysis focused on evaluating the efficacy of the different endoscopic procedures. Methods – Search was restricted to randomized controlled trials (RCTs) on MedLine, Cochrane, SciELO, and EMBASE for patients with chronic GERD (>6 months), over 18 years old and available follow up of at least 3 months. The main outcome was to evaluate the efficacy of the different endoscopic treatments compared to sham, pharmacological or surgical treatment. Efficacy was measured by different subjective and objective outcomes. Results – We analyzed data from 16 RCT, totaling 1085 patients. The efficacy of endoscopic treatments compared to sham and proton pump inhibitors (PPIs) treatment showed a significant difference up to 6 months in favor of endoscopy with no heterogeneity ($P<0.00001$) ($I^2$: 0%). The subgroup analysis showed a statistically significant difference up to 6 months in favor of endoscopy: endoscopy vs PPI ($P<0.00001$) ($I^2$: 39%). Endoscopy vs sham ($P=0.00001$) ($I^2$: 0%). Most subjective and objective outcomes were statistically significant in favor of endoscopy up to 6 and 12 months follow up. Conclusion – This systematic review and meta-analysis shows a good short-term efficacy in favor of endoscopic procedures when comparing them to a sham and pharmacological or surgical treatment. Data on long-term follow up is lacking and this should be explored in future studies.

INTRODUCTION

Gastroesophageal reflux disease (GERD) is a disease defined as a chronic condition resulting from the reflux of gastroduodenal contents into the esophagus and adjacent organs. It is characterized by symptoms of retrosternal burning (heartburn) and acid regurgitation. Occurring in 6.3% of the US adult population at a frequency of at least twice a week (1,2), there has been an increasing prevalence of GERD (10%-20%) in adults in Western populations in recent decades. It is estimated that up to 28% of adults have weekly symptoms of retrosternal burning and acid regurgitation (3). In Brazil, about 12% of the population is affected by the disease (4).

The symptoms of persistent mild reflux affect the physical, psychological well-being and quality of life of patients. Uncontrolled GERD can result in complications, including erosive esophagitis, with consequent peptic stenosis, and extraesophageal manifestations that require additional therapy. GERD also increases the risk of developing Barrett’s esophagus and subsequent esophageal adenocarcinoma. Recent reports demonstrate a worldwide increase in the annual incidence of esophageal cancer in parallel with the increasing prevalence of GERD (5,6).

The use of proton pump inhibitors (PPIs) in conjunction with lifestyle modifications continues to be the primary therapy. However, the effectiveness of this intervention is often hampered by adherence, costs and risks associated with the long-term use of PPIs. Anti-reflux surgery is an option for patients with refractory symptoms or in those in whom medical therapy is contraindicated or undesirable. Surgery is based on the reconstruction of the antireflux barrier, usually associated with the posterior closure of the diaphragmatic hiatus. These operations can be performed in an open fashion and more recently laparoscopically (7,8).

Surgical treatment, although effective in the short term, may be associated with non-negligible morbidity and there is a growing concern about late recurrence (9). Although conventional surgery has an acceptable safety profile, there has been increasing interest in alternative minimally invasive endoscopic treatments that may offer similar results with an increased safety profile and faster recovery times.

Endoscopic therapies have emerged as a possible treatment options for individuals with GERD, particularly when refractory to the use of PPIs. These techniques can be categorized into three groups: 1) Endoluminal suture or plication of the gastro-esophageal...
Coronel MA, Bernardo WM, Moura DTH, Moura ETH, Ribeiro IB, Moura EGH. The efficacy of the different endoscopic treatments versus sham, pharmacologic or surgical methods for chronic gastroesophageal reflux disease: a systematic review and meta-analysis

The efficacy of the different endoscopic treatments versus sham, pharmacologic or surgical methods for chronic gastroesophageal reflux disease: a systematic review and meta-analysis

The efficacy of the different endoscopic treatments versus sham, pharmacologic or surgical methods for chronic gastroesophageal reflux disease: a systematic review and meta-analysis

Two meta-analysis recently described on the literature, one showing an overall increased benefit of transoral incisionless fundoplication (TIF) performed with the EsophyX® device when compared to patients who did not undergo TIF\textsuperscript{(11)}. The second study analyzing the Stretta® procedure, showed that there were no significant changes in physiologic parameters (time spent at a pH less than 4 and lower esophageal sphincter pressure (LESP), ability to stop PPIs, or health related quality of life score (HRQL) when compared with sham therapy\textsuperscript{(22)}. The aim of our study is to perform a systematic review and meta-analysis on the efficacy of all randomized controlled trials evaluating the efficacy of all available endoscopic treatments when compared to a sham procedure or therapy with pharmacologic agents like PPIs or laparoscopic anti reflux surgery (LARS).

METHODS

Protocol and registration

The present systematic review and meta-analysis is performed according with the PRISMA statement\textsuperscript{(19)}. This study was registered at www.crd.york.ac.uk/PROSPERO. Registration number is: CRD42017064534. This study was exempt from ethical approval because analysis involved only de-identify data.

Search strategy

We searched in MedLine (Pubmed), EMBASE, Cochrane Central and SciELO (1980 to March 22, 2018), for the studies assessing the efficacy of all endoscopic treatment for GERD.

Terms used to search Medline

“Gastric Acid Reflux,” or “Esophageal Acid reflux “Gastroesophageal Reflux Disease,” or “GERD” AND “Endoscopic treatment,” or “Gastrointestinal Endoscopy,” or “Surgical Procedures,” or “Gastrointestinal Surgeries”.

Terms used to search in EMBASE, Cochrane Central, SciELO

(Gastroesophageal reflux disease) AND (“Endoscopic treatment” or “Gastrointestinal Surgical treatment”).

The search was restricted to human studies with no language or date of publication restriction in peer- reviewed journals. Two authors (M.C. and B.W.) independently screened each of the potential titles, abstracts in the primary study to exclude studies that did not address the research question of interest, based on pre-specified inclusion and exclusion criteria (detailed below). The full text of the remaining articles was examined to determine whether it contained relevant information. Areas of disagreement or uncertainty in article selection were resolved by consensus, and in discussion with a coauthor (D.T.M). Conference proceedings, which did not undergo peer review, were excluded from our analysis. We attempted to contact the corresponding authors to provide additional information on trials if required.

Study selection

Selection of prospective, randomized clinical trials evaluating the efficacy of the different endoscopic treatments versus any other interventions (sham, PPI, surgery) for chronic GERD was performed. Studies that met the following criteria were included: patients over 18 years of age, undergoing endoscopic procedures for chronic GERD (defined as symptoms equal or over 6 months in duration), more than 3 months follow up period. Types of intervention and controls: Available endoscopic therapies: transoral incisionless fundoplication (TIF2) by the EsophyX® device, surgical plication by NDO surgical® device, radiofrequency therapy by the Stretta® device; endoscopic suturing system by EndoCinch® device, injectable esophageal prostheses by Gatekeeper® device, biocompatible non-resorbable copolymer by the Enteryx® device. Controls were performed via a sham procedure, pharmacological treatments (PPIs) or surgery (LARS). Exclusion criteria: retrospective, prospective non-randomized, studies without full text, studies that were requested to the authors without being answered and studies that compare two endoscopic procedures head to head.

Data extraction and quality assessment

Data on study characteristic, such as, author name, reference, year of publication; sample size and population, type of endoscopic intervention, type of control group (sham, PPI or LARS), subjective or objective outcomes, follow-up period and type of analysis (per protocol or intention to treat) were abstracted onto a standardized data form by at least two authors independently (M.C, B.W, D.T.M). Details of data abstraction are reported in FIGURE 1. The quality of each study was classified according to the risk for bias, considering: the question to be investigated, a correct randomization protocol, an adequate subject allocation, an objective outcome measure, an adequate follow up period and type of analysis.

FIGURE 1. Flow diagram of the data extraction methodology.
The efficacy of the different endoscopic treatments versus sham, pharmacologic or surgical methods for chronic gastroesophageal reflux disease: a systematic review and meta-analysis

The importance of the blinding, patient losses in each study, each prognostic factor, outcome reporting and analysis by intention to treat or by protocol. In addition, the JADAD scale or score was used to independently assess the methodological quality of each clinical trial. (FIGURE 2.A and FIGURE 2.B).

Outcomes assessed

The main or primary outcome of the study is to measure the overall efficacy of endoscopic treatments versus other interventions (PPI or LARS) or sham procedure for the treatment of chronic GERD. Subgroup analysis was assessed individually.
for 3, 6 and 12 months follow up for the different outcomes. The outcomes were categorized as objective: 1) normalization of esophageal acid pH (total proportion of time with a pH <4 in 24-h period\(^{13}\)); 2) mean percent of total time of esophageal pH <4 in 24-hours period\(^{15}\); 3) healing esophagitis; 4) worsening esophagitis; 5) mean number of reflux episodes; 6) lower esophageal sphincter resting pressure (LESRP); and subjective: 1) time in remission (more than 6 months without the use of PPI); 2) number of patients with GERD health related quality of life (HRQL) score >50 % improvement\(^{16,17}\); 3) mean GERD HRQL score\(^{16,17}\); 4) elimination of troublesome regurgitation as defined as per the Montreal consensus\(^{18}\); 5) heartburn score\(^{19}\); 6) DeMeester score\(^{20}\). All extracted data were placed according to the intention-to-treat analysis and protocol information.

For this meta-analysis, if there was treatment crossover to other interventions, no data analysis was performed.

### Statistical analysis

This meta-analysis follows the methodology as previously suggested by DerSimonian and Laird\(^{18}\). We used a fixed-effect model to determine the efficacy of all endoscopic treatments vs any other type of interventions. Heterogeneity was assessed using the F statistic to estimate what proportion of total variances across studies was due to heterogeneity or chance. As previously reported, F values of 25%, 50%, and 75% represent low, moderate, and high levels of heterogeneity, respectively. Once heterogeneity was noted, to identify potential sources of heterogeneity, subgroup analysis was performed by excluding potential outliers. Visual inspection of publication bias was performed using a funnel plot and calculated by the Egger test\(^{20}\). The absolute risk difference with a 95% confidence intervals (CIs) were calculated for all point estimates, and a P value <0.05 was considered statistically significant. The difference between the main outcome as well as the subgroup analysis was calculated using the risk difference with dichotomous variables and the mean difference with continuous variables. The Mantel Hanzel test for the analysis of categorical variables and inverse variance for continuous variables. The number need to treat (NNT) was also calculated. Statistical analysis was performed using the RevMan 5.3 software (Copenhagen, The Nordic Cochrane Center, The Cochrane Collaboration, 2014) and VassarStats software: Website for Statistical Computation (Richard Lowry 2001-2017 All rights reserved).

### RESULTS

A total of 5491 citations were identified by using our search strategy (PubMed, SciELO, EMBASE, and Cochrane databases, provided 4984, 29, 276, and 202 articles respectively) we excluded 5,084 abstracts after initial screening, and assessed 407 full-text articles for eligibility. Of these, 391 studies did not meet inclusion criteria (animal trials, no outcome data available, abstracts, retrospective, duplicate population not randomized, comparison between two endoscopic procedures, comparison of a different technique of the same endoscopic treatment and not relevant). Thus, 16 prospective randomized clinical trials were selected for the final analysis. The schematic diagram of the study selection is illustrated in FIGURE 1. The characteristics of the included studies are summarized in TABLE 1. A total of 1085 patients were included in the analysis of the endoscopic treatment efficacy in comparison with sham procedure, PPI or LARS. A total of 221 patients underwent TIF2, 145 surgical plications, 81 radiofrequency therapy; 42 endoscopic suturing, 32 injectable esophageal prostheses and 75 biocompatible non-resorbable copolymer. As for the control group a total of 294 patients underwent a sham procedure, 120 received PPIs, 6 PPIs and 32 injectable esophageal prostheses.

### TABLE 1. Descriptive table of RTC’s characteristics.

| Study/ Publication Year | Population | Intervention Group | Control Group | Outcome (Efficacy) | Follow up (Months) | Final Analysis |
|-------------------------|------------|-------------------|--------------|--------------------|-------------------|---------------|
| Hikansson, 2015\(^{20}\) | Chronic GERD: 44 | TIF2: 22 | sham: 22 | Time in remission | 6 | ITT |
| Hunter, 2015\(^{20}\) | Chronic GERD: 129 | TIF2/placebo: 87 | sham + PPI: 42 | ETSR | 6 | ITT |
| Rinsma, 2013\(^{35}\) | Chronic GERD: 47 | TIF2: 32 | PPI: 15 | GERD HRQL score | 6 | ITT |
| Witterman, 2013\(^{31}\) | Chronic GERD: 60 | TIF2: 40 | PPI: 20 | >50% GERD HRQL | 6 | PP |
| Trad, 2013\(^{32}\) | Chronic GERD: 63 | TIF2: 40 | PPI: 23 | ETSR | 6 | PP |
| Kandlstorfer, 2013\(^{33}\) | Chronic GERD: 70 | NDO surgical: 37 | LARS: 33 | DeMeester score | 3 | ITT |
| Corley, 2003\(^{34}\) | Chronic GERD: 64 | Stretta: 35 | sham: 29 | >50% GERD HRQL | 6 | PP |
| Arts, 2011\(^{35}\) | Chronic GERD: 22 | Stretta: 11 | sham: 11 | GERD HRQL score | 3 | ITT |
| Antoniou, 2012\(^{36}\) | Chronic GERD: 60 | NDO surgical: 30 | LARS: 30 | GERD HRQL score | 3-12 | PP |
| Schwartz, 2007\(^{37}\) | Chronic GERD: 60 | Endocinch: 20 | sham: 20 | ETSR | 3 | ITT |
| Fockens, 2010\(^{38}\) | Chronic GERD: 118 | Gate Keeper: 75 | sham: 43 | GERD HRQL score | 6 | PP |
| Devière, 2005\(^{39}\) | Chronic GERD: 64 | Enteryx: 32 | sham: 32 | >50% GERD HRQL | 3 | ITT |
| Rothstein, 2006\(^{40}\) | Chronic GERD: 159 | NDO surgical: 78 | sham: 81 | >50% GERD HRQL | 3 | ITT |
| Coron, 2008\(^{41}\) | Chronic GERD: 43 | Stretta: 23 | PPI: 20 | Time in remission | 6-12 | ITT |
| Montgomery, 2006\(^{42}\) | Chronic GERD: 46 | Endocinch: 22 | sham: 24 | Time in remission | 3 | ITT |
| Aziz, 2010\(^{43}\) | Chronic GERD: 36 | Stretta: 12 | sham: 12 | Time in remission | 12 | ITT |

GERD: gastroesophageal reflux disease, HRQL: health related quality of life, PPI: proton pump inhibitors, LARS: laparoscopic antireflux surgery, TIF: transoral incisionless fundoplication, ITT: intention to treat, ETSR: elimination of troublesome regurgitation, PP: per protocol.
and 63 underwent LARS. Studies consistently scored well on
description of study aims, description of main findings, clarity in
reporting of unplanned retrospective analyses, appropriate use of
statistical tests, and use of accurate main outcome measures,
and consistently scored poorly on blinding of subjects and assessors
and patent allocation.

According to the risk of bias assessment of each individual
study, we observed that a proper outcome description, a ques-
tion to be investigated, randomization, patient losses and subject
and group prognosis were properly reported. Adequate allocation was
done by 75% (12/16), double blinding was properly described by
40% (7/16) of trials and analysis by intention to treat was done by
the 63% (10/16) of the studies. All studies had a JADAD
scale over >3 with an overall average of 4.1. (FIGURE 2.A and
FIGURE 2.B).

Study outcomes

• Efficacy of endoscopic treatments versus sham and
PPI

A total of 707 patients, divided into 3, 6 and 12 follow up peri-
ods, from 10 trials were analyzed to evaluate the overall efficacy of
the different endoscopic treatment devices versus any other in-
tervention. Endoscopic treatments were performed in 395: Stretta®,
Enteryx®, TIF2, NDO surgical®, Endocinch®, and 312 patients
from the control group received: sham, PPI, sham + PPI together.

The overall risk-difference analysis (RD) showed a statistically
significance difference (P<0.00001) in evaluating the treatment ef-
ficacy between the two groups (RD -0.35, 95% CI -0.42, -0.28), in
favor of endoscopic treatment and demonstrating no heterogeneity
between the trials (I²: 0%). The Number needed to treat (NNT)
was: 2.85. Endoscopic treatments were effective in treating chronic
GERD in 62% of the patients in comparison to the 25% of patients
from the control group.

For the 3 months follow up subgroup analysis, a total of 263
patients from three trials were included. The RD showed a statisti-
cally significance difference (P<0.00001) for the treatment efficacy
between the two groups (RD -0.38, 95% CI -0.49, -0.28), in favor
of endoscopic treatment and demonstrating no heterogeneity
between the trials (I²: 0%). The NNT was 2.63. For the 6 months
follow up subgroup analysis, a total of 377 patients from 6 trials
were included. The RD showed no statistically significance differ-
ce (P<0.06) for the treatment efficacy between the two groups (RD -0.36, 95% CI -0.45, -0.26) in favor of endoscopic treat-
ments and demonstrating low heterogeneity between the trials (I²:
7%). The NNT was 2.77. For the 12 months follow up subgroup
analysis, a total of 67 patients from two trials were included. The
RD showed no statistically significance difference (P<0.06) for the
treatment efficacy between the two groups (RD -0.20, 95% CI -0.41,
-0.01) with no heterogeneity between trials (I²: 0%). (FIGURE 3).

• Subgroup analysis

We decided to make a subgroup analysis for the efficacy of the
different endoscopic procedures to any type of intervention and
to only sham procedure.

![FIGURE 3. Efficacy of endoscopic treatments versus sham and PPI.](image-url)
• Efficacy of endoscopic treatments versus pharmacological (PPI) treatment

A total of 320 patients from four trials were analyzed. Follow up was divided in 6 and 12 periods. Endoscopic interventions were performed in 200 patients: Stretta®, TIF2, and 120 patients from the control group received: PPI and sham + PPI. The overall RD analysis showed a statistically significance difference ($P<0.00001$) in treatment efficacy between the two groups (RD -0.33, 95% CI -0.43, -0.22), favoring the endoscopic treatments and demonstrating a low heterogeneity between the trials ($I^2$: 39%). The NNT was 3.03. The different endoscopic treatments were effective in treating chronic GERD in 69% of the patients in compared to the 37% of patients treated with PPIs or sham + PPI.

For the 6 months follow up subgroup analysis, a total of 277 patients from four trials were included. The RD showed a statistically significance difference ($P<0.00001$) for the treatment efficacy between the two groups (RD -0.34, 95% CI -0.45, -0.24) favoring endoscopic treatments and demonstrating a moderate heterogeneity between the trials ($I^2$: 45%). The NNT was 2.94.

For the 12 months follow up subgroup analysis, a total of 43 patients from one trial were included. The RD showed no statistically significance difference ($P=0.15$) between the two groups (RD -0.22, 95% CI -0.51, 0.08). (FIGURE 4).

• Efficacy of endoscopic treatments vs sham procedure

A total of 387 patients, from 6 trials were included. Follow up was divided in 3, 6 and 12-month periods. Endoscopic interventions were performed in 195 patients: Stretta®, Enteryx®, TIF2, NDO surgical®, Endocinch®, and 192 patients underwent sham procedure for control.

The overall RD analysis showed a statistically significance difference ($P<0.00001$) in treatment efficacy between the two groups (RD -0.37, 95% CI -0.46, -0.28), favoring the endoscopic treatments and demonstrating no heterogeneity between trials ($I^2$: 0%). The NNT was 2.70. The different endoscopic treatments were effective in treating chronic GERD in 54% of the patients in comparison to the 17% of patients treated with sham.

For the 3 months follow up subgroup analysis, a total of 263 patients from three trials were included. The RD showed a statistically significance difference ($P<0.00001$) in evaluating the treatment efficacy between the two groups (RD -0.38, 95% CI -0.49, -0.28) favoring endoscopic treatments and demonstrating no heterogeneity between the trials ($I^2$: 0%). The NNT was: 2.63.

For the 6 months follow up subgroup analysis, a total of 100 patients from two randomized trials were included. The RD showed a statistically significance difference ($P<0.00001$) in evaluating the treatment efficacy between the two groups (RD -0.39, 95% CI -0.57, -0.21) favoring endoscopic treatments and demonstrating no heterogeneity between the trials ($I^2$: 0%). The NNT was: 2.56.

For the 12 months follow up subgroup analysis. Total of 24 patients from 1 randomized trial were included. The RD showed no statistically significance difference ($P<0.17$) between the two groups (RD -0.17, 95% CI -0.41, 0.07). (FIGURE 5).

• Summary of objective outcomes analyzed

Endoscopic therapies had consistent results showing a statistically significant ($P<0.00001$) (RD -0.42, 95% CI -0.62, -0.21) ($I^2$: 0%) improvement in healing of esophagitis with no heterogeneity between trials in up to 12 months of follow up. The outcomes of normalization of esophageal acid pH ($P<0.03$) (RD -0.13, 95% CI -0.26, -0.01) ($I^2$: 76%), LESRP ($P<0.00001$) (MD -1.15, 95% CI -1.47, -0.83) ($I^2$: 94%), mean percent of total time of esophageal pH<4 ($P<0.00001$) (MD -1.19, 95% CI -1.53, -0.84) ($I^2$: 78%) and mean number of reflux episodes ($P<0.00001$) (MD -12.80, 95% CI -14.60, -11.00).

![FIGURE 4. Efficacy of endoscopic treatments versus pharmacological (PPI) treatment.](image-url)
Coronel MA, Bernardo WM, Moura DTH, Moura ETH, Ribeiro IB, Moura EGH. The efficacy of the different endoscopic treatments versus sham, pharmacologic or surgical methods for chronic gastroesophageal reflux disease: a systematic review and meta-analysis.

Coronel MA, Bernardo WM, Moura DTH, Moura ETH, Ribeiro IB, Moura EGH. The efficacy of the different endoscopic treatments versus sham, pharmacologic or surgical methods for chronic gastroesophageal reflux disease: a systematic review and meta-analysis.

-15.04, -10.56) (I²: 98%) were statistically significant in favor to the endoscopic procedures but with a high heterogeneity between trials in up to 12 months of follow up, with the exemption of the mean number of reflux episodes which was statistically significant up to 3 months follow up. When comparing endoscopic therapies only to sham, the results are similar, except for healing of esophagitis since there is no available data to show this comparison.

**Summary of subjective outcomes analyzed**

When endoscopic treatments were compared to any other intervention (PPIs or LARS) or sham, the time in remission (P<0.00001) (RD -0.29, 95% CI -0.38, -0.20) (I²: 0%), number of patients with GERD HRQL score >50% improvement (P<0.00001) (RD -0.47, 95% CI -0.57, -0.37) (I²: 11%), elimination of troublesome regurgitation (P<0.00001) (RD -0.32, 95% CI -0.43, -0.20) (I²: 99%), were statistically significant in favor to the endoscopic procedures with very low heterogeneity between the trials up to 6 and 12 months follow up. Interestingly, the mean GERD HRQL score (P<0.00001) (MD -0.92, 95% CI -1.24, -0.60) (I²: 98%), the heartburn score (P<0.00001) (MD -0.53, 95% CI -0.60, -0.46) (I²: 80%) and DeMeester score (P<0.00001) (MD -5.14, 95% CI -6.43, -3.84) (I²: 96%), showed statistically significance in favor to endoscopy up to 6 and 12 months follow up. As stated above, endoscopic treatments for GERD can be categorized into three groups: 1. Endoluminal suture or plication of the gastroesophageal junction; 2. Radiofrequency (RF) thermal therapy of the lower esophageal sphincter (LES); and 3. Injection/implantation of biopolymers in GEJ. This meta-analysis compares the efficacy of different endoscopic procedures to any other intervention (sham procedure, PPIs or LARS). The efficacy of these treatments was measured by different objective and subjective outcomes.

As for the main outcome, which evaluates the general efficacy of the different endoscopic procedures versus sham and PPIs, we observed an overall statistically significant difference favoring the endoscopic procedures with no heterogeneity between the randomized clinical trials. Endoscopic treatment was more effective in treating chronic GERD in 62% of the patients, in comparison to 25% of patients treated by any of these interventions. In the individual subgroup analysis, we observed a statistically significant difference in favor of the endoscopic procedures in the 3 and 6 months follow up groups, but this difference was not present in studies that
Coronel MA, Bernardo WM, Moura DTH, Moura ETH, Ribeiro IB, Moura EGH. The efficacy of the different endoscopic treatments versus sham, pharmacologic or surgical methods for chronic gastroesophageal reflux disease: a systematic review and meta-analysis

There are several studies comparing laparoscopic surgery to PPIs. A randomized study described by Galmiche et al.(8) comparing LARS versus PPI with a 5-year follow up, showed that both groups presented higher rates of “time in remission” (for LARS, defined as need for acid suppressive therapy and for PPIs, as inadequate symptom control after dose adjustment). A similar, large randomized trial by Hatlebakk et al.(37) comparing LARS vs PPIs at 6-months and 5-years follow up, showed that both therapies were effective in controlling esophageal acid exposure. In our study, the time in remission and esophageal acid exposure rates were statistically significant in up to 6 months with no heterogeneity and 12 months with high heterogeneity, respectively, in favor of endoscopic treatments.

In the review, most of the studies report clinically significant moderate to severe postprocedure related adverse events such as epigastric pain, musculoskeletal pain, dysphagia, sore throat, chest pain, nausea and vomiting, bloating and flatulence among others, that were treated clinically, with complete resolution and no major sequelae. Reporting a total of 312 events of 1073 procedures. The event rate of 38% for the endoscopic treatments, 24% for the sham procedure, 4% for the PPI group and 2% for the LARS group.

However, there are studies that have reported more serious procedure related adverse events. A trial that evaluated the Gatekeeper device(39), showed two procedure related esophageal wall perforations, one managed surgically and other clinically with no long-term sequelae. A trial evaluating the NDO device, described a procedure related pneumomediastinum and pneumoperitoneum(40), managed clinically and without any further intervention. A trial assessing the NDO vs LARS(33), reported one post-procedure gastric bleeding related to the NDO device, managed clinically without sequelae. From all trials, one death at 11 months after the intervention (TIF2) was reported(31), this mortality case was considered probably unrelated to the intervention.

This meta-analysis provides outcomes of all the endoscopic procedures available to date to treat patients with chronic GERD. Since this patient population is similar across these studies and physiologically, all endoscopic therapies attempt to increase the pressure of the LES by different mechanisms, pooling the results of these RCTs in a systematic fashion, provides a detailed analysis of objective and subjective outcomes that may aid in bridging the gap between medical therapy and conventional surgery in patients who suffer from chronic GERD.

CONCLUSION

The development of alternative treatment options for chronic GERD is of interest. Patients are destined to lifelong PPIs or antireflux surgery, although current conventional surgical approaches have been well studied and are relatively safe, recent advances in minimally invasive endoluminal techniques have introduced the possibility of incisionless procedures.

This systematic review and meta-analysis shows a good short-term efficacy in favor of endoscopic procedures when comparing them to a sham and pharmacological or surgical treatment. Current data on endoluminal therapies for the management of GERD are promising; however, the role of endoscopy within the GERD treatment algorithm remains unclear. More studies, especially in endoscopic plication devices, are necessary because the current available data are limited by conflicting results, lack of long-term efficacy and non-homogeneous outcome reporting. In conclusion, larger prospective, multicenter, randomized studies are necessary,
to identify the role of endoscopic therapies before they can be advocated as an effective GERD solution.

ACKNOWLEDGEMENTS

We will like to thank all the authors and colleagues who contributed to this meta-analysis. To Dr. Cesar de Clemente Junior, Dr. Emmanuel Coronel and Dr. Paulo Sakai for contributing in writing the manuscript.

REFERENCES

1. Camilleri M, Dubois D, Coulie B, Jones M, Kahrlis PJ, Rentz AM, et al. Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: Results of the US upper gastrointestinal study. Clin Gastroenterol Hepatol. 2005;3:543-52.

2. Moraes-Filho JPP, Chinzon D, Eising JN, Hashimoto CL, Zaterka S. Prevalence of heartburn and gastroesophageal reflux disease in the urban Brazilian population. Arq Gastroenterol. 2005;42:122-7.

3. El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastroesophageal reflux disease: the present, the past and the future. Gut. 2014;63:1185-93.

4. Edgren G, Adami HO, Vainio EW, Nyrén O. A global assessment of the oesophageal adenocarcinoma epidemic. Gut. 2013;62:1406-14.

5. Demeester TR, Johnson LF, Kent AH. Evaluation of current operations for the prevention of gastroesophageal reflux. Ann Surg. 1974;180:511-25.

6. Boeckxstaens G, El-Serag HB, Smout AJPM, Kahrilas PJ. Symptomatic reflux disease: the present, the past and the future. Gut. 2014;63:1185-93.

7. Demeester TR, Johnson LF, Kent AH. Evaluation of current operations for the prevention of gastroesophageal reflux. Ann Surg. 1974;180:511-25.

8. Galmiche J-P, Hatlebakk J, Attwood S, Ell C, Fiocca R, Eklund S, et al. Laparoscopic antireflux surgery vs esophageal resection for chronic GERD: the LOTUS randomized clinical trial. JAMA. 2011;305:1969-77.

9. Spechler SJ, Lee E, Ahnem D, Goyal RK, Hirano I, Ramirez F, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA. 2001;285:2331-8.

10. Rothstein RI. Endoscopic therapy of gastroesophageal reflux disease: Outcome of the randomized-controlled trials done to date. J Clin Gastroenterol. 2008;42:594-602.

11. Huang X, Chen S, Zhao H, Zeng X, Lian J, Tseng Y, Chen J. Efficacy of transoral incisionless fundoplication (TIF) for the treatment of GERD: a systematic review with meta-analysis. Surg Endosc. 2017;31:1032-44.

12. Lippa S, Kumar A, Richter JE. No evidence for efficacy of radiofrequency ablation for treatment of gastroesophageal reflux disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2015;13:1058-67.e1

13. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.

14. Jadad, A. Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12.

15. Vakil N, van Zanten S V, Kahrlis P, Dent J, Jones R, Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900-20; quiz 1943.

16. Velanovich V, Vallance S, Gusz J, Tappa F, Harkabu M. Quality of life scale for gastroesophageal reflux disease. J Am Coll Surg. 1996;183:217-24.

17. Chan Y, Ching JYL, Cheung CMY, Tsai KK, Polder-Verkloodt S, Peng SH, et al. Development and validation of a disease-specific quality of life questionnaire for gastro-esophageal reflux disease: the GERD-QOL questionnaire. Aliment Pharmacol Ther. 2010;31:452-60.

18. Jamieson JR, Stein HJ, DeMeester TR, Bonavina L, Schwizer W, Hinder RA, et al. Ambulatory 24-h esophageal pH monitoring: normal values, optimal thresholds, specificity, sensitivity, and reproducibility. Am J Gastroenterol. 1992;87:1102-11.

19. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88.

20. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991;337:867-72.

21. Testoni PA, Testoni S, Mazzoleni G, Vailati C, Passaretti S. Long-term efficacy of transoral incisionless fundoplication with Esophyx (TIF 2.0) and factors affecting outcomes in GERD patients followed for up to 6 years: a prospective single-center study. Surg Endosc Other Interv Tech. 2015;29:2770-80.

22. Dughera L, Rotondano G, De Cinco M, Cussolin P, Cisaro F. Durability of partial stent radiofrequency treatment for GERD: Results of an 8-year follow-up. Gastroenterol Res Pract. 2014;2014:531907.

23. Noor M, Squires P, Noor E, Lee M. Long-term maintenance effect of radiofrequency energy delivery for refractory GERD: a decade later. Surg Endosc Other Interv Tech. 2015;19:2323-33.

24. Zachler J, Roy-Shapira A, Bonavina L, Babayea A, Kieslich R, Schoppmann SF, et al. Endoscopic anterior fundoplication with the Medigus Ultrasonic Surgical Endostapler (MUSETM) for gastroesophageal reflux disease: 6-month results from a multi-center prospective trial. Surg Endosc. 2015;29:220-9.

Authors’ contributions

Study concept and design by Coronel MA, Bernardo WM and Moura EGH; acquisition of data, analysis and interpretation of data, statistical analysis by Coronel MA, Bernardo WM, Moura DTH, Moura ETH, Ribeiro IB; drafting of the manuscript and critical revision of the manuscript for important intellectual content by Coronel MA, Bernardo WM, Moura EGH; Study supervision: Bernardo WM, Moura DTH and Moura EGH.
Coronel MA, Bernardo WM, Moura DTH, Moura ETH, Ribeiro IB, Moura EGH. The efficacy of the different endoscopic treatments versus sham, pharmacologic or surgical methods for chronic gastroesophageal reflux disease: a systematic review and meta-analysis.

25. Kim HJ, Kwon C-I, Kessler WR, Selzer DJ, McNulty G, Babaye A, et al. Long-term follow-up results of endoscopic treatment of gastroesophageal reflux disease with the MUSETM endoscopic stapling device. Surg Endosc. 2016;30:3402-8.

26. ASGE Technology Committee, Thosani N, Goodman A, Manfredi M, Nava- neethan U, Parsi MA, et al. Endoscopic anti-reflux devices. Gastrointest Endosc. 2017;86:931-48.

27. Hatlebakk JG, Zerbib F, Bruley des Varannes S, Attwood SE, Eil C, Fiocca R, et al. Gastroesophageal acid reflux control 5 years after antireflux surgery, compared with long-term esomeprazole therapy. Clin Gastroenterol Hepatol. 2016;14:678-685 e3.

28. Häkansson B, Montgomery M, Cadiere GB, Rajan A, Bruley des Varannes S, Lerhun M, et al. Randomized clinical trial: Transoral incisionless fundoplication vs. sham intervention to control chronic GERD. Aliment Pharmacol Ther. 2015;42:1261-70.

29. Hunter JG, Kahrilas PJ, Bell RCW, Wilson EB, Trad KS, Dolan JP, et al. Efficacy of transoral fundoplication vs omeprazole for treatment of regurgitation in a randomized controlled trial. Gastroenterology. 2015;148:324-33.

30. Rinsma NF, Farré R, Bouvy ND, Maslee AAM, Conchillo JM. The effect of endoscopic fundoplication and proton pump inhibitors on baseline impedance and heartburn severity in GERD patients. Neurogastroenterol Motil. 2015;27:220-8.

31. Witteman BPL, Conchillo JM, Rinsma NF, Betzel B, Peeters A, Koek GH, et al. Randomized controlled trial of transoral incisionless fundoplication vs. proton pump inhibitors for treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2015;110:531-42.

32. Trad KS, Barnes WE, Simoni G, Shaghoury AB, Mavrelis PG, Raza M, et al. Transoral incisionless fundoplication effective in eliminating GERD symptoms in partial responders to proton pump inhibitor therapy at 6 months. Surg Innov. 2015;22:26-40.

33. Kandlstoffer A, Koch OO, Antoniou SA, Asche K-U, Grenderath FA, Pointner R. A randomized trial on endoscopic full-thickness gastroplasty versus laparoscopic antireflux surgery in GERD patients without hiatal hernias. Surg Laparosc Endosc Percutan Tech. 2013;23:212-22.

34. Corley DA, Katz P, Wo JM, Stefan A, Patti M, Rothstein R, et al. Improvement of gastroesophageal reflux symptoms after radiofrequency energy: a randomized, sham-controlled trial. Gastroenterology. 2003;125:668-76.

35. Arts J, Bisschops R, Blondeau K, Farré R, Vos R, Holvoet L, et al. A double-blind sham-controlled study of the effect of radiofrequency energy on symptoms and distensibility of the gastro-esophageal junction in GERD. Am J Gastroenterol. 2012;107:222-30.

36. Antoniou SA, Koch OO, Kandlstoffer A, Asche KU, Berge J, Grenderath FA, et al. Endoscopic full-thickness plication versus laparoscopic fundoplication: a prospective study on quality of life and symptom control. Surg Endosc. 2012;26:1063-8.

37. Schwartz MP, Wellink H, Goossen HG, Conchillo JM, Samsom M, Smout. Endoscopic gastroplasty for the treatment of gastrooesophageal reflux disease: a randomised, sham-controlled trial. Gut. 2007;56:20-8.

38. Focken P, Cohen L, Edmundowicz SA, Binnmöller K, Rothstein RI, Smith D, et al. Prospective randomized controlled trial of an injectable esophageal prosthesis versus a sham procedure for endoscopic treatment of gastroesophageal reflux disease. Surg Endosc Other Interv Tech. 2010;24:1387-97.

39. Devière J, Costamagna G, Neuhaus H, Voderholzer W, Louis H, Tringali A, et al. Nonresorbable copolymer implantation for gastroesophageal reflux disease: A randomized sham-controlled multicenter trial. Gastroenterology. 2005;128:532-40.

40. Rothstein R, Filipi C, Caca K, Pruitt R, Mergener K, Torquati A, et al. Endoscopic full-thickness plication for the treatment of gastroesophageal reflux disease: a randomized, sham-controlled trial. Gastroenterology. 2006;131:704-12.

41. Coron E, Sebille V, Cadiot G, Zerbib F, Ducrotte P, Ducrot F, et al. Clinical trial: Radiofrequency energy delivery in proton pump inhibitor-dependent gastro-oesophageal reflux disease patients. Aliment Pharmacol Ther. 2008;28:1147-58.

42. Montgomery M, Håkanson B, Ljungqvist O, Ahlman B, Thorell A. Twelve months’ follow-up after treatment with the EndoCinch endoscopic technique for gastro-oesophageal reflux disease: A randomized, placebo-controlled study. Scand J Gastroenterol. 2006;41:1382-9.

43. Abdel Aziz AM, El-Khayat HR, Sadek A, Mattar SG, McNulty G, Kongkam P, et al. A prospective randomized trial of sham, single-dose Stretta, and double-dose Stretta for the treatment of gastroesophageal reflux disease. Surg Endosc Other Interv Tech. 2010;24:818-25.